Online inquiry

IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5352MR)

This product GTTS-WQ5352MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5352MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ466MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ530MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ6505MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ13087MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ8053MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ6631MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ11119MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ14274MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG7155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW